DELFI Diagnostics Presents Additional Promising Proof-of-Concept Data on its Monitoring Program at AACR 2023

ORLANDO, Fla., April 18, 2023 /PRNewswire/ — DELFI Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, presented proof-of-concept data demonstrating how DELFI’s platform can be used for…

Leave a Reply

Your email address will not be published. Required fields are marked *